Abstract
Hereditary tyrosinemia type I (HTI) is a rare autosomal recessive disorder caused by a fumarylacetoacetate hydrolase (FAH) deficiency. If untreated, its acute form is characterized by hepatic failure, renal dysfunction and neurological crisis, and may lead to death. Due to a genetic founder effect in the French-Canadian population, the prevalence of HTI is increased in the province of Quebec (1/19 819), with the IVS12 + 5G>A (1062 + 5G>A) splice site mutation responsible for more than 90% of mutated alleles. Universal newborn screening for (HT1) was thus established in 1970, and close to four million infants have been tested so far, allowing to identify 185 of the 190 affected newborns. During the 1970–1997 period, 2,249,000 newborns were screened at 3–7 days of life on dried filter paper blood spots by tyrosine (Tyr) concentration followed by indirect colorimetric semi-quantitative and quantitative (Q) succinylacetone (SA) testing (red blood cells δ-aminolevulinate dehydratase inhibition), with immunoreactive FAH as the confirmatory test. This approach allowed to identify 118 of 123 affected newborns. In 1998, owing to earlier hospital discharge and increased rate of breastfeeding, four cases were missed within the same year as the discriminating power of blood Tyr became inadequate. Thus, the screening algorithm was modified: indirect semi-quantitative SA measurement became the first-tier test between 1998 and 2014, and direct SA measurement by tandem mass spectrometry (MS/MS) was implemented in 2014, followed by indirect quantitative SA measurement as second tier test. Confirmation is performed by plasmatic amino acid profile and molecular testing. During the 1998–2016 period, more than 1,5 million neonates have been tested (90% sampled between 24 and 48 h of life): 67 of the 67 HTI cases were identified. Both indirect and direct SA measurement as the initial HTI screening test proved to be highly sensitive and specific, with positive and negative predicting value of 79% and 100% respectively.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Andermann A, Blancquaert I, Beauchamp S, Costea I (2011) Guiding policy decisions for genetic screening: developing a systematic and transparent approach. Public Health Genomics 14(1):9–16. doi:10.1159/000272898
Angileri F, Bergeron A, Morrow G, Lettre F, Gray G, Hutchin T, Ball S, Tanguay RM (2015) Geographical and ethnic distribution of mutations of the fumarylacetoacetate hydrolase gene in hereditary tyrosinemia type 1. JIMD Rep 19:43–58. doi:10.1007/8904_2014_363
De Braekeleer M, Larochelle J (1990) Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St-Jean. Am J Hum Genet 47(2):302–307
Grenier A, Laberge C (1996) Neonatal screening for tyrosinemia type I and early sampling. In: Proceedings of the Third International Society for Neonatal Screening, Boston, Oct 20–23
Grenier A, Belanger L, Laberge C (1976) alpha1-Fetoprotein measurement in blood spotted on paper: discriminating test for hereditary tyrosinemia in neonatal mass screening. Clin Chem 22(7):1001–1004
Grompe M, St-Louis M, Demers SI, al-Dhalimy M, Leclerc B, Tanguay RM (1994) A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I. N Engl J Med 331(6):353–357. doi:10.1056/NEJM199408113310603
Halvorsen S (1980) Screening for disorders of tyrosine metabolism. In: Bickel H, Guthrie R, Hammerson G (eds) Neonatal screenings for inborn errors of metabolism. Springer, New York
JMG W, Jungner G, World Health Organization (1968) Principles and practice of screening for disease, Public Health Papers, vol 34. World Health Organization, Geneva
Laberge C (1969) Hereditary tyrosinemia in a French Canadian isolate. Am J Hum Genet 21(1):36–45
Laberge C, Dallaire L (1967) Genetic aspects of tyrosinemia in the Chicoutimi region. Can Med Assoc J 97(18):1099–1101
Laberge C, Grenier A, Valet JP, Morissette J (1990) Fumarylacetoacetase measurement as a mass-screening procedure for hereditary tyrosinemia type I. Am J Hum Genet 47(2):325–328
Laberge AM, Michaud J, Richter A, Lemyre E, Lambert M, Brais B, Mitchell GA (2005) Population history and its impact on medical genetics in Quebec. Clin Genet 68(4):287–301. doi:10.1111/j.1399-0004.2005.00497.x
Mitchell GA, Grompe M, Lambert M, Tanguay RM (2001) Hypertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw Hill, New York, pp 1777–1806
Poudrier J, St-Louis M, Lettre F, Gibson K, Prevost C, Larochelle J, Tanguay RM (1996) Frequency of the IVS12 + 5G–>A splice mutation of the fumarylacetoacetate hydrolase gene in carriers of hereditary tyrosinaemia in the French Canadian population of Saguenay-Lac-St-Jean. Prenat Diagn 16(1):59–64. doi:10.1002/(SICI)1097-0223(199601)16:1<59::AID-PD810>3.0.CO;2-D
Scott CR (2006) The genetic tyrosinemias. Am J Med Genet C: Semin Med Genet 142C(2):121–126. doi:10.1002/ajmg.c.30092
van Spronsen FJ, Thomasse Y, Smit GP, Leonard JV, Clayton PT, Fidler V, Berger R, Heymans HS (1994) Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 20(5):1187–1191
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Giguère, Y., Berthier, MT. (2017). Newborn Screening for Hereditary Tyrosinemia Type I in Québec: Update. In: Tanguay, R. (eds) Hereditary Tyrosinemia. Advances in Experimental Medicine and Biology, vol 959. Springer, Cham. https://doi.org/10.1007/978-3-319-55780-9_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-55780-9_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-55779-3
Online ISBN: 978-3-319-55780-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)